Further enzyme kinetic study indicated that compounds 1 and 13 inhibited PTP1B activity in a noncompetitive manner, suggesting that these compounds might be potential lead compounds for the development of anti-obesity and anti-diabetic drugs. The gene discussed is PTPN1; the disease is obesity due to melanocortin 4 receptor deficiency.